Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiteVax UPEC vaccine
- Development stage
- Preclinical
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
01
Overview
LiteVax UPEC vaccine is a prophylactic vaccine candidate designed to prevent urinary tract infections (UTIs) caused by uropathogenic *Escherichia coli* (UPEC). Developed by LiteVax, the vaccine utilizes the company's proprietary CMS (Carbohydrate-based Multi-component System) adjuvant technology to enhance the immune response against UPEC antigens. The project, known as UTOPIA and supported by the EUROSTARS program, is currently in the preclinical stage of development. The vaccine aims to provide a preventative solution for recurrent UTIs, potentially reducing the reliance on antibiotic treatments and addressing the growing concern of antimicrobial resistance in uropathogens.
- Other names
- UTOPIA (EUROSTARS)
02
Targets
FimH (Type 1 fimbrial adhesin)
Beyond the preview
Go deeper on LiteVax UPEC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiteVax UPEC vaccine.